Li Li

机构：University of Utah, Heilongjiang Academy of Sciences, Yancheng Second People's Hospital · ORCID：0000-0003-0935-8634

发表论文 58 篇 · 总被引 1203 次 · h-index 18

代表论文

• Preclinical evaluation and pilot clinical study of [18F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts (2021 · Acta Pharmaceutica Sinica B · 被引 91)
• 18F- or 177Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention (2022 · European Journal of Nuclear Medicine and Molecular Imaging · 被引 66)
• Radiosynthesis and Preclinical Evaluation of Bispecific PSMA/FAP Heterodimers for Tumor Imaging (2022 · Pharmaceuticals · 被引 35)
• Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816. (2022 · Journal of Clinical Oncology · 被引 21)
• CYLD mediates human pulmonary artery smooth muscle cell dysfunction in congenital heart disease‐associated pulmonary arterial hypertension (2021 · Journal of Cellular Physiology · 被引 18)
• Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non‐small cell lung cancer: A retrospective study (2023 · Thoracic Cancer · 被引 17)